Testosterone replacement therapy will lead klinefelter syndrome therapeutics sales through 2036 with 48.0% of the therapeutics segment in 2026. The market was valued at USD 1.26 billion in 2025 and is expected to be worth USD 2.11 billion by 2036, creating an incremental opportunity of USD 0.79 billion.